Table 2:

Adverse events

Toxicity	Events		Patients
	Grade 3/4	Any grade	Grade 3/4		Any grade
			n	%	n	%
Most likely related to Erdafitinib
Oral mucositis	5	58	5	14%	27	77%
Hyperphosphatemia	0	56	0	0%	29	83%
Palmar-plantar erythrodysesthesia syndrome	4	36	3	9%	18	51%
Diarrhea	0	30	0	0%	14	40%
Constipation	0	25	0	0%	19	54%
Dysgeusia	0	25	0	0%	19	54%
Dry mouth	0	22	0	0%	18	51%
Nail alterations	0	19	0	0%	13	37%
Sore throat	1	18	1	3%	8	23%
Alopecia	0	16	0	0%	13	37%
Elevated AST	4	14	2	6%	7	20%
Dry skin	0	13	0	0%	12	34%
Epistaxis	0	12	0	0%	9	26%
Anorexia	0	11	0	0%	7	20%
Dry eye	1	11	1	3%	10	29%
Skin ulceration	9	10	2	6%	2	6%
Elevated ALT	4	8	2	6%	5	14%
Vision changes/alterations	1	7	1	3%	6	17%
Abdominal pain	0	5	0	0%	5	14%
Dizziness	0	5	0	0%	3	9%
Gastroesophageal reflux disease	0	5	0	0%	5	14%
Hypotension	2	4	1	3%	3	9%
Colitis	2	2	1	3%	1	3%
Esophagitis	1	2	1	3%	2	6%
Eye keratopathy	1	2	1	3%	1	3%
Hyperkeratosis	1	1	1	3%	1	3%
Syncope	1	1	1	3%	1	3%
Most likely related to Palbociclib
Neutropenia	44	74	22	63%	25	71%
Leucopenia	9	30	8	23%	15	43%
Anemia	3	23	3	9%	12	34%
Thrombocytopenia	4	21	12	34%	2	6%
Lymphopenia	1	7	1	3%	4	11%
Febrile neutropenia	1	1	1	3%	1	3%
Neutrophilia	1	1	1	3%	1	3%
Thromboembolic event	1	1	1	3%	1	3%
Likely related to the combination
Fatigue	1	50	1	3%	23	66%
Nausea	0	7	0	0%	6	17%
Vomiting	0	7	0	0%	6	17%

Grade 1, 2, 3 and 4 toxicities were recorded by the treating investigators, no grade 5 toxicities were experienced in this trial.